DRAPALIN makes history by becoming the first European wholesaler to import medical cannabis from Africa.
The wholesaler from Munich now has the first EU-GMP compliant medical cannabis strain from Africa in its portfolio. The medical cannabis produced in the landlocked South African country of Lesotho is currently imported exclusively by DRAPALIN to Germany.
Transparency is particularly important at DRAPALIN. Therefore, detailed information on the manufacturer, country of origin and production processes is openly available. After all, this is a herbal medicine whose quality is significantly influenced by the place where it grows, the cultivation conditions and, not least, the philosophy underlying its cultivation.
For this reason, DRAPALIN is particularly proud to have partnered with MG Health, a professional and reliable producer from Lesotho. MG Health grows its products at an altitude of 2000m, in a mountainous and pristine environment, completely isolated from any form of commercialized industry. Here you will find optimal conditions for the cultivation of medicinal cannabis: long sunny days, dry air, and the purest water.
With the support of DRAPALIN, MG Health succeeded in becoming the first African company ever to be recognized as a producer of non-irradiated medicinal cannabis according to EUGMP guidelines in Germany. This also means that it has guaranteed quality and production standards in the field of standardized medicinal plant cultivation – one of the prerequisites for exporting the product to Europe.
The partnership with MG Health benefits all sides. According to MG Health, their company was able to achieve numerous improvements for the local population in Marakabei through its social engagement. The cultivator reported that this includes not only creating more than 400 jobs but also building training centers and a library at their own expense, which has significantly increased the local school graduation rate.
“We are incredibly proud to be the first company to import medical cannabis from Africa. We have made history through the collaboration with our partner MG Health from Lesotho. The high THC product is a cross between the Californian strain White Lemon and the local strain Marakabei Local.” Lana Korneva, Co-Founder and Managing Director of Drapalin Pharmaceuticals Ltd.
About DRAPALIN
Since the “Cannabis as Medicine” law came into force in Germany in March 2017, an active market has emerged around this product in Europe. Drapalin Pharmaceuticals GmbH from Munich has all the necessary licenses for the import and trade of medical cannabis. In addition, the company sees itself as a reliable partner with regard to high-quality cannabis products and stands for transparency and security of supply.
DRAPALIN is a supporting member of the Verband der Cannabis versorgenden Apotheken e.V. (VCA), founding and presidium member of the industry association Branchenveband Cannabiswirtschaft e.V. (BvCW) and member of the German Pharmaceutical Industry Association (Bundesverband der Pharmazeutischen Industrie e.V.).
Media contact
Florian Wemhoff
Tel.: +49 (89) 277 801 327
E-Mail: presse@drapalin.de
Drapalin Pharmaceuticals GmbH, Paul-Heyse-Str. 28, 80336 München
More information at www.drapalin.de
